PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2020 | 10 | 1 | 18-22
Article title

Chemotherapy with trifluridine/tipiracil prolongs progression-free survival time and improves quality of life A case report of 59-year-old woman with metastatic rectal cancer

Content
Title variants
Languages of publication
EN
Abstracts
EN
The paper presents a clinical case of a patient with a long-term response to IV line chemotherapy with trifluridine/tipiracil. The treatment allowed to maintain a good quality of life with acceptable side effects.
Discipline
Publisher

Journal
Year
Volume
10
Issue
1
Pages
18-22
Physical description
Contributors
  • Oncology and Hematology Department, Beskid Oncology Centre – John Paul II Memorial City Hospital in Bielsko-Biala
References
  • 1. European Medicines Agency. European public assessment report (EPAR) for Lonsurf. 2016. http://www.ema.europa.eu.
  • 2. Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treatment Rev. 2015; 41: 777-83.
  • 3. Mayer R, Van Cutsem E, Falcone A et al.; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015; 372: 1909-19.
  • 4. Funaioli C, Longobardi C, Martoni AA. The impact of chemotherapy on overall survival and quality of life of patients with metastatic colorectal cancer: a review of phase III trials. J Chemother. 2008; 20: 14-27.
  • 5. Van Cutsem E, Falcone A, Garcia-Carbonero R et al. Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial. ESMO Open. 2017; 2(5): e000261.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-3b49fa70-b0d6-4869-ac23-c0014fcd27c7
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.